Saskia A J Lesnik Oberstein Selected Research

Notch3 Receptor

1/2022	NOTCH3 variant position is associated with NOTCH3 aggregation load in CADASIL vasculature.
1/2020	Naturally occurring NOTCH3 exon skipping attenuates NOTCH3 protein aggregation and disease severity in CADASIL patients.
1/2019	The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant.
4/2016	Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept.
12/2015	The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation.
6/2014	Interpretation of NOTCH3 mutations in the diagnosis of CADASIL.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Saskia A J Lesnik Oberstein Research Topics

Disease

12	CADASIL 01/2022 - 12/2010
3	Cerebral Small Vessel Diseases 01/2022 - 12/2012
3	Stroke (Strokes) 12/2020 - 04/2016
1	Cognitive Dysfunction 12/2020
1	Dementia (Dementias) 01/2020
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 04/2016
1	Lacunar Stroke 12/2010
1	Krause-Kivlin syndrome 09/2006

Drug/Important Bio-Agent (IBA)

8	Cysteine (L-Cysteine)FDA Link 01/2022 - 06/2014
6	Notch3 ReceptorIBA 01/2022 - 06/2014
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2016
2	Epidermal Growth Factor (EGF)IBA 01/2019 - 04/2016
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2015
1	Amino Acids FDA Link 11/2016
1	Antisense OligonucleotidesIBA 04/2016
1	IronIBA 12/2012
1	Phenobarbital (Luminal)FDA Link 12/2010
1	GlycosyltransferasesIBA 09/2006

Therapy/Procedure

2	Therapeutics 04/2016 - 12/2015